Related Experiment Video
Updated: Jul 4, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Natural products reshape osteosarcoma cell fate: promoting cell death
Binghan Yan1,2, Junli Chang1,2, Peng Zhao1,2
1Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Abstract:
Osteosarcoma is the most prevalent primary malignant bone tumor in children and adolescents. Despite advancements in adjuvant chemotherapy and surgical techniques, the overall survival rate of osteosarcoma patients remains suboptimal, particularly in cases of metastatic or recurrent disease. Programmed cell death (PCD), a highly regulated process that includes apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis, plays a pivotal role in determining cellular fate (survival and death). In osteosarcoma, PCD dysregulation enables malignant cells to evade cell death signals, thereby accelerating tumor development. Natural products derived from various medicinal plants and dietary components exhibit promising potential for osteosarcoma treatment by regulating PCD through different mechanisms. With advantages such as low cost, minimal side effects, and wide availability, natural products have attracted considerable attention for translational research. This review systematically synthesizes current knowledge on PCD subtypes in osteosarcoma and elucidates the molecular mechanisms by which natural products regulate PCD to inhibit the development of osteosarcoma. By integrating these insights, we aim to offer novel perspectives for developing targeted therapeutic strategies and improving clinical outcomes in osteosarcoma patients.
Insights
Natural products show promise in treating osteosarcoma by regulating programmed cell death (PCD) pathways. This review explores how these natural compounds can inhibit tumor development for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma is a primary bone cancer in children and adolescents with poor survival rates for metastatic or recurrent cases.
- Programmed cell death (PCD) is crucial for cell fate, and its dysregulation drives osteosarcoma progression by allowing cancer cells to evade death signals.
- Current treatments for osteosarcoma have limitations, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To review the subtypes of programmed cell death (PCD) in osteosarcoma.
- To elucidate the molecular mechanisms by which natural products regulate PCD in osteosarcoma.
- To explore the potential of natural products as a therapeutic approach for osteosarcoma.
Main Methods:
- Systematic literature review of programmed cell death (PCD) in osteosarcoma.
- Analysis of molecular mechanisms of natural products affecting PCD pathways.
- Synthesis of current knowledge on natural product-based therapies for osteosarcoma.
Main Results:
- PCD dysregulation is a key factor in osteosarcoma development and progression.
- Natural products from medicinal plants and dietary sources can modulate various PCD pathways (apoptosis, autophagy, ferroptosis, pyroptosis, necroptosis).
- Natural products offer a promising, low-cost, and safe therapeutic avenue for osteosarcoma treatment.
Conclusions:
- Targeting PCD pathways with natural products presents a viable strategy to inhibit osteosarcoma growth.
- Further research into natural products could lead to improved therapeutic interventions and clinical outcomes for osteosarcoma patients.
- Natural products offer a translational research opportunity for developing novel osteosarcoma treatments with minimal side effects.
Related Concept Videos
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...